IFNB1 and myeloid sarcoma: Downer et al. (2011) also demonstrated that PBMCs from MS patients are refractory to poly(I:C) treatment, in terms of IFN-β expression, thus indicating that blood cells from MS patients may show TLR3 tolerance (Downer et al., 2011).